KEAP1 and chronic kidney disease: Other studies reported that allicin exerts beneficial effects in experimental PAH and CKD through the prevention of cardiac hypertrophy; improvement of endothelial, cardiac, and renal function; blocking of the interaction of Ang II with the AT1 receptor; and the modulation of oxidative status by the Nrf2/Keap1 pathway [22,23,25,46].